Quinazoline Compound For Inducing Degradation Of G12 D Mutation Kras

< Back

Quinazoline Compound For Inducing Degradation Of G12 D Mutation Kras Protein

Abstract: [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Solution] The present inventors have examined a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer, and have found that a quinazoline compound has an excellent activity of inducing the degradation of G12D-mutation KRAS protein and an activity of inhibiting a G12D-mutation KRAS, and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The quinazoline compound or a salt thereof according to the present invention can be used as a therapeutic agent for pancreatic cancer.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #

Filing Date

05 September 2023

Publication Number

40/2023

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ASTELLAS PHARMA INC.

5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Inventors

1. YOSHINARI, Tomohiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

2. ISHIOKA, Hiroki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

3. KAWAMINAMI, Eiji

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

4. WATANABE, Hideyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

5. KAWAGUCHI, Kenichi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

6. KURAMOTO, Kazuyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

7. IMAIZUMI, Tomoyoshi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

8. MORIKAWA, Takahiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

9. HAMAGUCHI, Hisao

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

10. IMADA, Sunao

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

11. OKUMURA, Mitsuaki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

12. NAGASHIMA, Takeyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

13. INAMURA, Kohei

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Specification

Documents

Application Documents

#	Name	Date
1	202347059548-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [05-09-2023(online)].pdf	2023-09-05
2	202347059548-STATEMENT OF UNDERTAKING (FORM 3) [05-09-2023(online)].pdf	2023-09-05
3	202347059548-PROOF OF RIGHT [05-09-2023(online)].pdf	2023-09-05
4	202347059548-PRIORITY DOCUMENTS [05-09-2023(online)].pdf	2023-09-05
5	202347059548-FORM 1 [05-09-2023(online)].pdf	2023-09-05
6	202347059548-DECLARATION OF INVENTORSHIP (FORM 5) [05-09-2023(online)].pdf	2023-09-05
7	202347059548-COMPLETE SPECIFICATION [05-09-2023(online)].pdf	2023-09-05
8	202347059548-RELEVANT DOCUMENTS [26-09-2023(online)].pdf	2023-09-26
9	202347059548-MARKED COPIES OF AMENDEMENTS [26-09-2023(online)].pdf	2023-09-26
10	202347059548-FORM 13 [26-09-2023(online)].pdf	2023-09-26
11	202347059548-Annexure [26-09-2023(online)].pdf	2023-09-26
12	202347059548-AMMENDED DOCUMENTS [26-09-2023(online)].pdf	2023-09-26
13	202347059548-FORM-26 [20-10-2023(online)].pdf	2023-10-20
14	202347059548-FORM 3 [14-02-2024(online)].pdf	2024-02-14
15	202347059548-FORM 18 [27-09-2024(online)].pdf	2024-09-27